Memantine combined with environmental enrichment improves spatial memory and alleviates Alzheimer's disease-like pathology in senescence-accelerated prone-8 (SAMP8) mice

Journal of Biomedical Research

Volumn 26, Issue 6, 2012, Pages 439-447

  Dong, Jingde ^a   Zhou, Mi ^a   Wu, Xiaoqiang ^a   Du, Mingyang ^a   Wang, Xiaoshan ^a  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease (AD); Environmental enrichment; Memantine; SAMP8 mouse; Spatial memory

Indexed keywords

AMYLOID BETA PROTEIN; MEMANTINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL ENRICHMENT; HIPPOCAMPAL CA1 REGION; LEARNING; MALE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE ACCELERATED MOUSE; SPATIAL MEMORY;

EID: 84870926527     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.26.20120053     Document Type: Article

References (48)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
2. Price DL, Koo EH, Unterbeck A Cellular and molecular biology of Alzheimer's disease. Bioessays 1989, 10:69-74.
3. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ Evidence that the 42-and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996, 93:13170-13175.
4. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003, 4:97-112.
5. Parsons CG, Stöffler A, Danysz W Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007, 53:699-723.
6. Bakchine S, Loft H Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2007, 11:471-479.
7. McShane R, Areosa Sastre A, Minakaran N Memantine for dementia. Cochrane Database Syst Rev 2006, (2). CD003154.
8. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
9. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
10. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacol 1999, 38:735-767.
11. Drever BD, Anderson WG, Johnson H, O'Callaghan M, Seo S, Choi DY, et al. Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimers Dis 2007, 12:319-333.
12. Schneider LS, Dagerman KS, Higgins JP, McShane R Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011, 68:991-998.
13. van Praag H, Kempermann G, Gage FH Neural consequences of environmental enrichment. Nat Rev Neurosci 2000, 1:191-198.
14. Herring A, Lewejohann L, Panzer AL, Donath A, Kröll O, Sachser N, et al. Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiol Dis 2011, 42:530-538.
15. Herring A, Ambrée O, Tomm M, Habermann H, Sachser N, Paulus W, et al. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Exp Neurol 2009, 216:184-192.
16. Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2005, 25:5217-5224.
17. Takeda T, Hosokawa M, Takeshita S, Irino M, Higuchi K, Matsushita T, et al. A new murine model of accelerated senescence. Mech Ageing Dev 1981, 17:183-194.
18. Dong H, Yuede CM, Coughlan C, Lewis B, Csernansky JG Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease. Neuropsychopharmacology 2008, 33:3226-3236.
19. Morris RGM Spatial localization does not require the presence of local cues. Learn Motiv 1981, 12:239-260.
20. Akiyama H, Tago H, Itagaki S, McGeer PL Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease. Acta Neuropathol 1990, 79:537-544.
21. Schwab C, Steele JC, McGeer PL Dystrophic neurites are associated with early stage extracellular neurofibrillary tangles in the parkinsonism-dementia complex of Guam. Acta Neuropathol 1997, 94:486-492.
22. Yamamoto T, Hirano A A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986, 12:3-9.
23. Lin X, Zhang Y, Dong J, Zhu X, Ye M, Shi J, et al. GM-CSF enhances neural differentiation of bone marrow stromal cells. Neuroreport 2007, 18:1113-1117.
24. Schwab C, Steele JC, McGeer PL Pyramidal neuron loss is matched by ghost tangle increase in Guam parkinsonism-dementia hippocampus. Acta Neuropathol 1998, 96:409-416.
25. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010, 176:870-880.
26. Cacabelos R Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and de-pression. Methods Find Exp Clin Pharmacol 2007, 29(Suppl A):1-91.
27. Ray B, Banerjee PK, Greig NH, Lahiri DK Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett 2010, 470:1-5.
28. Lipton SA, Rosenberg PA Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994, 330:613-622.
29. Eijkenboom M, Blokland A, van der Staay FJ Modelling cognitive dysfunctions with bilateral injections of ibotenic acid into the rat entorhinal cortex. Neuroscience 2000, 101:27-39.
30. Kopniczky Z, Dochnal R, Mácsai M, Pál A, Kiss G, Mihály A, et al. Alterations of behavior and spatial learning after unilateral entorhinal ablation of rats. Life Sci 2006, 78:2683-2688.
31. Wittenberg GM, Tsien JZ An emerging molecular and cellular framework for memory processing by the hippocampus. Trends Neurosci 2002, 25:501-505.
32. Heinemann U, Schmitz D, Eder C, Gloveli T Properties of entorhinal cortex projection cells to the hippocampal formation. Ann N Y Acad Sci 2000, 911:112-126.
33. Braak H, Braak E Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995, 16:271-278.
34. deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004, 25:1197-1203.
35. Stoub TR, deToledo-Morrell L, Stebbins GT, Leurgans S, Bennett DA, Shah RC Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA 2006, 103:10041-10045.
36. Reitz C, Honig L, Vonsattel JP, Tang MX, Mayeux R Memory performance is related to amyloid and tau pathology in the hippocampus. J Neurol Neurosurg Psychiatry 2009, 80:715-721.
37. Morley JE The SAMP8 mouse: a model of Alzheimer disease. Biogerontology 2002, 3:57-60.
38. Pallas M, Camins A, Smith MA, Perry G, Lee HG, et al. From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J Alzheimers Dis 2008, 15:615-624.
39. Morley JE, Farr SA, Kumar VB, Banks WA Alzheimer's disease through the eye of a mouse. Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides 2002, 23:589-599.
40. Farr SA, Banks WA, Uezu K, Sano A, Gaskin FS, Morley JE Antibody to betaamyloid protein increases acetylcholine in the hippocampus of 12 mon SAMP8 male mice. Life Sci 2003, 73:555-562.
41. Adlard PA, Perreau VM, Pop V, Cotman CW Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005, 25:4217-4221.
42. Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, et al. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging 2007, 28:831-844.
43. Görtz N, Lewejohann L, Tomm M, Ambrée O, Keyvani K, Paulus W, et al. Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice. Behav Brain Res 2008, 191:43-48.
44. Pardon MC, Sarmad S, Rattray I, Bates TE, Scullion GA, Marsden CA, et al. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels. Neurobiol Aging 2009, 30:1099-1113.
45. Ambrée O, Leimer U, Herring A, Görtz N, Sachser N, Heneka MT, et al. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol 2006, 169:544-552.
46. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
47. Herring A, Blome M, Ambrée O, Sachser N, Paulus W, Keyvani K Reduction of cerebral oxidative stress following environmental enrichment in mice with Alzheimer-like pathology. Brain Pathol 2010, 20:166-175.
48. Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol 2008, 18:32-39.